Today: 20 May 2026

Standard Chartered share price rebounds after Thursday slide — CFO change, crypto push, earnings next

Standard Chartered share price rebounds after Thursday slide — CFO change, crypto push, earnings next

Standard Chartered shares rose 0.6% to 1,740.5 pence in early London trading Friday after a 4.7% drop the previous session. The bank named Peter Burrill interim CFO following Diego De Giorgi’s sudden exit. Standard Chartered also announced a digital assets partnership with B2C2 and disclosed a 9.14% stake in Polestar Automotive. UK stocks broadly fell Thursday as the FTSE 100 slipped 0.7%.
13 February 2026
···
NatWest profit beats forecasts, lifts targets and rolls out £750m buyback — while NWG shares cling to 600p

NatWest profit beats forecasts, lifts targets and rolls out £750m buyback — while NWG shares cling to 600p

NatWest reported a 24% rise in 2025 pretax operating profit to £7.7 billion and announced a £750 million share buyback for early 2026. The bank lifted its 2028 return target and proposed a 51% higher annual dividend. Shares fell 2.55% Thursday after a volatile week following its £2.7 billion deal to acquire Evelyn Partners. Assets under management grew 20% to £58.5 billion before the deal.
13 February 2026
···
Barclays share price today: stock edges up as £1bn buyback starts and first trades hit the tape

Barclays share price today: stock edges up as £1bn buyback starts and first trades hit the tape

Barclays shares rose 0.6% in early London trading Friday after the bank began a £1 billion share buyback, with 7.29 million shares repurchased since Feb. 11. JPMorgan is executing the purchases on the London Stock Exchange. Senior managers Craig Bright and Taalib Shaah disclosed share sales earlier in the week. The buyback runs through Aug. 10, subject to regulatory approval.
13 February 2026
·
Unilever share price set for test after €1.5 billion buyback meets cautious 2026 outlook

Unilever share price set for test after €1.5 billion buyback meets cautious 2026 outlook

Unilever expects 2026 growth at the lower end of its 4%-6% target and announced a €1.5 billion share buyback set for the second quarter. Shares fell up to 3.6% after the update, as the company flagged modest margin improvement and plans to sell its 19.9% stake in The Magnum Ice Cream Company. Magnum’s shares dropped over 14% after its first standalone earnings report.
13 February 2026
··
British American Tobacco share price: BAT set for spotlight after AI job-cut warning and 2026 buyback plan

British American Tobacco share price: BAT set for spotlight after AI job-cut warning and 2026 buyback plan

BAT shares closed down 0.5% at 4,404p Thursday after the company warned an AI-led productivity drive could mean job cuts. Full-year revenue fell 1% to £25.61 billion, while adjusted profit from operations rose 2.3% to £11.28 billion. BAT raised its dividend 2% and announced a £1.3 billion buyback for 2026. The company said U.S. action on illicit vapes could cut unregulated market share by a third.
13 February 2026
··
RELX share price today: £450m buyback and AI talk in focus before London open

RELX share price today: £450m buyback and AI talk in focus before London open

RELX shares closed up 1.94% at 2,052 pence Thursday after reporting 2025 revenue of £9.59 billion and expanding its share buyback by £450 million through March. The company bought 1.4 million shares Thursday and has acquired 10.24 million since January 2. RELX proposed a final dividend of 48.0 pence per share, payable June 18. Investors remain focused on AI risks and the pace of buybacks.
13 February 2026
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 13.02.2026

Soybean futures rose 11 to 13¼ cents Thursday, with November up 5¾ cents, after the USDA reported a 108,000 MT export sale to Egypt and China bought 286,100 MT. Weekly export sales hit a marketing year low but stayed 141% above last year. Soybean meal futures climbed, while soybean oil futures fell. Brazil’s crop estimate increased; Argentina’s held steady with lower crop ratings.
13 February 2026
Twilio (TWLO) stock slips after-hours on 2026 outlook — what investors watch next

Twilio (TWLO) stock slips after-hours on 2026 outlook — what investors watch next

Twilio shares fell 2.2% to $107.95 in after-hours trading Thursday after the company posted a 14% revenue rise to $1.37 billion and forecast 2026 revenue growth of up to 12.5%. The results beat analyst estimates, but the stock is down 22.4% year-to-date. Twilio reported over 402,000 active customer accounts and $1.1 billion remaining on its buyback authorization. The company expects higher carrier fees to reduce gross margin in 2026.
13 February 2026
···
Expedia (EXPE) stock drops after hours even as 2026 outlook tops estimates

Expedia (EXPE) stock drops after hours even as 2026 outlook tops estimates

Expedia forecast 2026 gross bookings of $127–$129 billion and revenue of $15.6–$16.0 billion, both above analyst estimates. Shares fell 2.6% to $227.24 in late after-hours trading after a volatile session. Fourth-quarter revenue rose 11% to $3.547 billion, with B2B gross bookings up 24%. The company declared a $0.48 dividend and repurchased 9 million shares for $1.7 billion.
13 February 2026
··
Dutch Bros stock price jumps after hours as earnings beat hits — what BROS investors watch next

Dutch Bros stock price jumps after hours as earnings beat hits — what BROS investors watch next

Dutch Bros shares jumped 12.3% to $57.07 in after-hours trading after reporting Q4 revenue up 29% to $443.6 million and same-shop sales up 7.7%. The company forecast 2026 revenue of $2.0-$2.03 billion and at least 181 new shop openings. Adjusted earnings were 17 cents a share, beating analysts’ 9-cent estimate. The stock had closed down 5% at $50.82.
13 February 2026
··
1 … 263 264 265 266 267 … 1,959

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Go toTop